CG Oncology, Inc. Common stock beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.70 | $-0.90 | -28.6% | Miss |
| Q12026 FY2026 | $-0.58 | $-0.71 | -22.4% | Miss |
| Q42025 FY2025 | $-0.61 | $-0.51 | +16.4% | Beat |
Back to CGON overview · CGON holders · CGON KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.